Abstract
The metastasizing capacity of the rat pancreatic adenocarcinoma BSp73ASML (ASMLwt) is strikingly reduced by a knockdown of CD44v4-v7 (ASMLkd). We used this model to analyze the role of the CD44 variant isoform (CD44v) in (pre)metastatic niche formation. Intrafootpad injections of ASMLwt-, but not ASMLkd-conditioned medium (CM), strongly promote settlement of ASMLkd cells in lymph nodes and lung. Fractionation of CM revealed a contribution by a soluble matrix and exosomes, where the CD44v6-containing ASMLwt-soluble fraction can complement ASMLkd-exosomes, but not vice versa. This implies that exosomes are the final actors, are CD44v-independent, but require a soluble matrix, which depends on CD44v. Analyzing the composition revealed that only the ASMLwt-matrix contains c-Met and urokinase-type plasminogen activator receptor. In vitro, mostly ASMLwt-exosomes promote proliferation and induce gene expression in metastatic organ cells. However, in vivo corresponding changes in the (pre) metastatic organ are only observed when both, exosomes plus the soluble matrix, are provided. Thus, neither CD44v nor exosomes alone suffice for (pre)metastatic niche formation. Instead, CD44v suffices for assembling a soluble matrix, which allows exosomes, independent of their origin from poorly or highly metastatic cells, to modulate (pre) metastatic organ cells for tumor cell embedding and growth.
Introduction
Metastasis formation relies on an interaction with the primary tumor's surrounding [1], where a small population of cancer-initiating cells (CICs) [2,3] may account for metastasis formation by organizing a niche in the (pre)metastatic organ [3–5], which implies long-distance communication of CIC.
CICs are defined by a set of markers [3,6], one of which, CD44, is expressed in several types of leukemia and carcinoma [7]. CD44 contributes to hematopoietic and leukemic stem cell settlement [8,9]. It plays an important role in leukocyte and metastatic cell motility through hyaluronic acid (HA) binding [10] or association with integrins, cytoskeletal proteins, and metalloproteinases (MMPs) [11–14]. CD44 contributes to stem cell and metastatic cell mobilization by interacting with c-Met [15–17] and protects from apoptosis by interfering with receptor-mediated apoptosis and by activating antiapoptotic proteins [18,19]. Overexpression of CD44v6 promotes metastasis formation [20], which was confirmed by a selective knockdown of CD44v4-v7 (ASMLkd) [21] in the highly metastatic BSp73ASML cell line (ASMLwt) [22].
Settlement of metastasizing tumor cells is facilitated by the establishment of special niches in (pre)metastatic organs [23]. Niche preparation involves stimulation of local fibroblasts by tumor-derived factors and chemokines that attract tumor cells and hematopoietic progenitors [24], lysyl oxidase being important for marrow cell recruitment [25]. Nonetheless, information on long-distance communication between a tumor and the host organs is still limited. We suggest that tumor cells avail special delivery systems and hypothesize that a concerted activity between tumor-derived factors and exosomes is required [26].
Exosomes, small, multivesicular body (MVB)-derived vesicles, are abundantly released by tumor cells on fusion with the plasma membrane [27,28]. Exosomes harbor, besides a common set of membrane and cytosolic molecules, cell type-specific proteins that maintain functional activity [28–30]. Exosomes also contain messenger RNA (mRNA) and microRNA (miRNA) that are transferred to target cells, where they can be translated or mediate RNA silencing [31]. Exosomes function as a potent tool for intercellular communication and gene delivery also in metastasis [28,29].
To prove our hypothesis that tumor-derived factors suffice to promote metastasis formation, we made use of ASMLwt and ASMLkd cells. ASMLwt cells metastasize through the lymphatics to the lung but do not grow locally [22]. ASMLkd cells poorly metastasize, which might be a sequel of a defect in a CD44 variant isoform (CD44v)-assembled soluble matrix, which promotes adhesion and apoptosis resistance [21]. Because the ASML tumor does not grow locally, likely because of a defect in angiogenesis induction [22], this model should allow to study the role CD44v takes in creating a metastasis-supporting environment and to define which tumor-derived components suffice for the cross talk between a tumor and the (pre)metastatic organ.
Materials and Methods
Rats and Tumors
Specific pathogen-free BDX rats were fed sterilized food and water ad libitum. ASMLwt and ASMLkd clones of a BDX pancreatic adenocarcinoma [21,22], a BDX lung fibroblast (LuFb), a rat lymph node stroma (LnStr) [32], and a rat aortic endothelial cell line (RAEC) were maintained in RPMI-1640/10% fetal calf serum. Confluent cultures were trypsinized and split.
Antibodies
Primary antibodies are listed in Table W1. Streptavidin-HRP and dye-labeled secondary antibodies were obtained from Dianova, Hamburg, Germany.
Flow Cytometry
Cells (2–5 x 105) were stained according to routine procedures. For intracellular staining, cells were fixed and permeabilized. Samples were processed in a FACSCalibur using the Cell Quest program for analysis (BD, Heidelberg, Germany).
Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted using TRIzol reagent (Invitrogen, Karlsruhe, Germany). Reverse transcription-polymerase chain reaction followed routine procedures. Primers are listed in Table W2.
Cell and Tissue Preparation
Lymph nodes (LN), femur, and lung were aseptically removed. Bone marrow (BM) was flushed out of the femur, and the lung tissue was cut into small pieces. Tissues were meshed through fine gauze.
Fractionation of Conditioned Medium
Tumor cells were cultured for 24 hours in serum-free medium. The supernatant was collected and centrifuged (10 minutes at 1000g, 1500g, or 2000g). For vesicle depletion, this conditioned medium (CM) was centrifuged for 20 minutes at 10,000g and 90 minutes at 26,000g. The vesicle-depleted CM is termed “soluble fraction.” The soluble fraction contains a strongly adhesive subfraction [21], which was recovered as the plastic adherent fraction after culturing tumor cells for 24 hours in serum-free medium and removing the cells by EDTA treatment. Exosomes were pelleted by centrifugation (64,000g for 90 minutes) and resuspended in PBS.
SDS-PAGE and Western Blot
Samples were resolved on 10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes (30 V for 16 hours at 4°C), and membranes were blocked, blotted with streptavidin or primary and HRP-conjugated secondary antibodies (1 hour at room temperature) and developed with the ECL Kit (Amersham Life Sciences, Braunschweig, Germany). For matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) analysis, gels were fixed for 16 hours in 150 ml of ethanol, sensitized for 45 minutes in 0.3 M K-tetrathionate, 0.5 M K-acetate, and 30% ethanol. Gels were washed (H2O; six times for 10 minutes each) and incubated for 1 hour in 2% silver nitrate. Gels were developed in 0.5 M K-carbonate, 10% Na-thiosulfatepentahydrate, and 0.01% formalin. The reaction was stopped (0.5 M Tris-HCl, 2% acetic acid), and gels were washed (twice for 30 minutes each).
MALDI-TOF Mass Spectrometry
Gels were silver-stained. Protein digestion, sample preparation, MALDI-TOF fingerprint analysis, postsource decay fragmentation analysis, and database searches were performed as described [33].
Histology
Cryostat sections (5–7 µm) of snap-frozen tissue were fixed, stained with the indicated antibodies, washed, and exposed to biotinylated secondary antibodies and alkaline phosphatase-conjugated avidin-biotin complex solution. Sections were counterstained with hematoxylin. For fluorescence staining of deposited matrix, cells were grown for 48 hours on cover slides. Cells were removed by prolonged EDTA treatment, and slides were blocked and stained with the indicated antibodies and washed and mounted in Elvanol (Sigma Diagnostic, Munic, Germany). Digitized images were generated using a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany).
Proliferation Assay
Triplicates of LnStr, LuFb, RAEC (5 x 104) or LN or BM cells (LNCs or BMCs; 2 x 105) were cultured in the presence of CM or fractions thereof. Proliferation was determined after 48 hours by MTT staining.
Apoptosis Induction
Cells were cultured in 96-well plates in RPMI containing cisplatin (cis-diamineplatinum(II) dichloride; Sigma, Munich, Germany) and/or CM or fractions thereof. Survival was monitored after 48 hours by annexin V/propidium iodide or evaluation of the percentage of respiratory active cells (MTT assay).
Adhesion Assay
Cells (1 x 106) were suspended in RPMI, CM or fractions thereof and seeded on plastic or adhesive matrix-coated 24-well plates. After 30 minutes at 37°C, nonadherent cells were washed off. Adherent cells were fixed, crystal violet-stained, and lysed. Absorbance was measured at 595 nm. Adhesion is presented as percentage of input cells.
Migration Assay
Cells were seeded in the upper part of a Boyden chamber in 30 µl of RPMI/0.1% BSA. The lower part, separated by an 8-µm (adherent cells) or 5-µm (leukocytes) pore size polycarbonate membrane (Neuroprobe, Gaithersburg, MD), contained 30 µl of RPMI/0.1% BSA, CM, or fractions thereof. Leukocytes in the lower chamber were counted after 4 hours. Migration of adherent cells was evaluated after 16 hours by staining the lower membrane side with crystal violet. After lysis, OD at 595 nm was measured. Migration is presented as percentage of input cells. In wound healing assays, semiconfluent monolayers were scratched. Medium was changed adding RPMI, CM, or fractions thereof. Migration was documented after 24 to 48 hours by light microscopy.
Zymography
LnStr, LuFb, and RAEC were lysed after overnight culture in the presence of CM or fractions thereof. Lysates, CM, the soluble fraction, or exosomes were incubated with Laemmli buffer (15 minutes at 37°C) and separated in a 10% acrylamide/1 mg/ml gelatin gel. Gels were washed and stained with Coomassie blue.
In Vivo Assay
Female rats (10–14 weeks old) received five daily intrafootpad (IFP) injections (150 µg/25 µl) of control medium, CM, or fractions thereof at day 5 concomitantly with tumor cells (1 x 106) and, thereafter, two injections per week. Rats were killed after 4 to 28 days. The popliteal, inguinal, para-aortic, and mesenteric LN, BM, and lung were excised. Tissues were shock frozen or meshed. Animal experiments were approved by the local government authorities.
Statistics
Significance was calculated by the Student's t test. In vitro assays (triplicates) were repeated three times.
Results
ASMLwt CM Supports Metastatic Spread of ASMLkd Cells
To explore whether ASMLwt-derived soluble factors suffice to prepare a niche that allows embedding and growth of poorly metastatic ASMLkd cells, rats received 150 µg of ASMLwt-CM, IFP, on five consecutive days, at day 5 concomitantly with ASMLwt or ASMLkd cells. Thereafter, application of CM was repeated twice per week. Rats were killed, and draining LNs and lung was excised 4 to 28 days after tumor cell application. During this period, a significantly increased number of ASMLkd cells were recovered in draining LNs and lung in rats receiving ASMLwt-CM. No tumor cells were recovered in the lung of control rats (Figure 1, A and B). In addition, a higher number of leukocytes were recovered in ASMLkd-bearing rats that received ASMLwt-CM (Figure 1C). In ASMLwt-bearing rats, the number of tumor cells and of leukocytes was hardly affected by ASMLwt-CM (Figure 1, A–C). Strongly upregulated expression of CD49c, CD49d, and CD54 and distinctly upregulated expression of urokinase-type plasminogen activator receptor (uPAR) and vascular endothelial growth factor receptors 1 and 2 (VEGFR1 and VEGFR2) are prominent ASMLwt-CM-induced alterations in the popliteal LNs and the lung. Unexpectedly, because ASMLwt cells hardly induce angiogenesis, LNs contain few but very strongly CD31+ capillaries. CD31 expression is also upregulated in the lung. The most striking feature are CD11b+ clusters in the LNs, which, although smaller, are also seen in the lung (Figure 1D).
These data show that ASMLwt cells deliver messages that suffice for significant alterations in premetastatic organs, which allow a poorly metastatic cell line to reach, settle, and grow in LNs and the lung. We had shown before that ASMLwt cells deliver a soluble matrix, which supports tumor cell adhesion and apoptosis resistance [21], but also that tumor-derived exosomes can exert systemic effects such as angiogenesis induction in tumor-free organs [34]. Because of the large array of activities, which a tumor cell has to fulfill to reach the state of metastatic growth, we considered it unlikely that a single tumor-derived factor sufficed to account for premetastatic niche preparation and hence proceeded to evaluate whether the ASMLwt-derived soluble or the vesicular fraction, particularly exosomes, support ASMLkd cells in progressing through the metastatic cascade.
An ASMLwt-Soluble Fraction Cooperates with Exosomes to Support Metastatic Spread
To examine which components of the ASMLwt-CM account for the metastasis-supporting effect, a soluble fraction was separated from exosomes. Settlement of ASMLkd cells and leukocyte expansion/recruitment were more efficiently facilitated by ASMLwt-exosomes than the soluble fraction. However, neither exosomes nor the soluble fraction reached the efficacy of CM. Because it was apparent that both the soluble fraction and exosomes were required for accelerated metastatic spread, it was of interest whether both fractions must be derived from a metastatic tumor line. The evaluation of tumor cell recruitment into the draining LNs after application of ASMLkd-CM, the ASMLkd-soluble fraction, or the ASMLkd-exosomes revealed that ASMLkd-CM and ASMLkd-exosomes, but not the soluble fraction, supported, albeit weakly, tumor cell settlement. Applying a mixture of the soluble fraction and exosomes from ASMLwt and ASMLkd cells confirmed that ASMLkd-exosomes can cooperate with the ASMLwt-soluble fraction (Figure 2, A–C).
An ex vivo analysis of LNC confirmed a strong effect of ASMLwt-CM but only a weak effect of ASMLkd-CM on hematopoietic cell activation/expansion in (pre)metastatic organs. The ASMLwt-soluble fraction exerted no effect, and exosomes were very weakly effective; that is, CD49b, CD49c, CD49d, stromal-derived factor 1 (SDF-1), MMP9, MMP13, and uPAR expression only becomes stimulated by ASMLwt-CM but not by the ASMLwt-soluble fraction and slightly by ASMLwt-exosomes. However, upregulated gene expression was frequently seen after application of the ASMLwt-soluble fraction together with ASMLkd-exosomes (Figure 2D; examples on the relative increase in marker expression: Figure W1).
Thus, ASMLwt-CM creates a milieu that supports metastatic settlement of weakly metastasizing ASMLkd cells, but neither the ASMLwt-soluble fraction nor the ASMLwt-exosomes alone are sufficient. Instead, components of the ASMLwt-soluble fraction can cooperate even with ASMLkd-exosomes but not vice versa. These findings imply that exosomes contain essential messages that require the ASMLwt-soluble fraction for delivery. Hence, we examined differences between ASMLwt and ASMLkd cells, the soluble fraction, and exosomes.
Impact of CD44v on Gene Expression, Protein Secretion/Shedding, and Exosome Delivery
The plastic-deposited matrix of ASMLwt, but not ASMLkd cells, strongly supports adhesion of both ASMLwt and ASMLkd cells [21]. This “adhesive” fraction was evaluated for the presence of matrix proteins, growth factors, and proteases frequently deposited in the extracellular matrix. With the exception of a possibly more structured organization of HA in the ASMLwt-adhesive fraction, no obvious differences were observed between ASMLwt- and ASMLkd-matrix proteins. However, hepatocyte growth factor (HGF), MMP13, and uPA were reduced in the ASMLkd-matrix. Deposition of other MMPs, platelet-derived growth factor (PDGF), SDF-1, VEGF, and thrombospondin (TSP) was not overtly affected (Figure 3A and data not shown).
MALDI-TOF analysis revealed a strong reduction of c-Met and complement component 3 (C3) in the ASMLkd-soluble fraction and of annexin II, annexin V, heat shock protein 1 (HSP-1), phosphoglycerate kinase 1 (PGK-1), and monooxygenase activating protein in ASMLkd-exosomes.
Western blot confirmed that besides CD44v6, c-Met, uPAR, C3, HA synthase 3 (HAS3), and CD104 were selectively missing in the ASMLkd-soluble fraction. C-Met, uPAR, and HAS3 expression was also reduced in ASMLkd cells. Instead, C3 and CD104 were missing in the ASMLkd-soluble fraction, but expression was not reduced in ASMLkd cells (Figure 3B).
Exosomes are enriched in tetraspanins, tetraspanin-associated molecules, glycosylphosphatidylinositol-anchored, and other raft-associated molecules [27,29,30]. The recovery of the tetraspanins D6.1A, CD151, CD9 and of the D6.1A-associated molecules F2 alpha receptor regulatory protein, CD13, intersectin 2 (INS-2), epithelial cell adhesion molecule (EpCAM), and EpCAM-associated claudin-7 [27,35], as well as of CD11a, CD49c, CD49f, and CD104 was not or only slightly impaired in ASMLkd cells and exosomes. Even the integrin ligands laminin 5 and fibronectin (FN) were partly recovered in exosomes. However, HGF was absent, and recovery of annexin V, HSP-1, PGK-1, and TSP was strongly reduced in ASMLkd-exosomes. The expression of these proteins in ASMLkd cells was unimpaired (Figure 3C and data not shown). Zymography revealed a reduction of MMP9 in ASMLkd-exosomes (Figure 3D).
Taken together (Table W3), ASMLwt cells exhibit several features of pancreatic CICs that are mostly preserved in weakly metastatic ASMLkd cells. ASMLwt and ASMLkd cells express the CIC markers EpCAM, α6β4, CD24, CD133, and CD166 (Figure W2). The recovery of tetraspanins and tetraspanin-associated molecules remained unaltered in ASMLkd-exosomes. These findings might explain the metastasis-supporting activity of ASMLkd-exosomes. The deficit in HGF could account for the low efficacy of ASMLkd-exosomes. Supporting our hypothesis that exosomes are the driving force, but essentially require the soluble fraction, are the deficits of CD44v6, c-Met, uPAR, HAS3, and C3 in the ASMLkd-soluble fraction, c-Met, uPAR, and HAS3 even being reduced in ASMLkd cells.
Impact of CM on Potential Target Cells
To support our hypothesis for distinct tasks of the soluble fraction and exosomes and their cooperativity in (pre)metastatic niche preparation, we evaluated the impact of the ASMLwt and ASMLkd soluble fraction and exosomes on adhesion, migration, apoptosis resistance, and proliferation of potential target cells, namely, LnStr, LuFb, RAEC, LNC, and BMC, in vitro. In advance, we explored whether the soluble fraction and the exosomes exert a similar impact on adhesion molecule, protease, chemokine/cytokine, and receptor expression on LnStr, LuFb, RAEC, LNC, and BMC in vivo.
As expected, the soluble fraction and exosomes influenced gene expression when cocultured with potential target cells. However, distinct to the ex vivo analysis, the coculture system revealed that some of the ASMLwt-CM-mediated effects are also observed with ASMLkd-CM, although less pronounced. Furthermore, both the soluble fraction and exosomes can modulate target cell gene expression in vitro. The soluble fraction can influence adhesion molecule expression. Exosomes primarily influence growth factor receptor expression. Exosomes are also involved in the down-regulation of gene expression, mostly of growth factors. As anticipated, not all potential target cells are equally well responsive, and upregulated gene expression differs between distinct target cells. Some CM-mediated effects were seen with neither the soluble fraction nor the exosomes, which indicates that, even allowing for direct contact (coculture), target cell activation may require elements from both the soluble fraction and exosomes (Figure 4; detailed information: Figure W3).
These findings confirmed that both the soluble matrix and the exosomes exert an impact on premetastatic organs and that the soluble matrix and the exosomes display distinct activities. In addition, it is important to note that in vitro exosomes influenced the expression of a large array of genes, which has not been seen in vivo. We interpret the finding in the sense that, in vivo, the soluble matrix is required for the delivery of exosomal messages.
Taking that the CM exerted similar effects in vivo and in vitro and assuming that the less-pronounced effects of separated exosomes in vivo compared with in vitro are related to inefficient targeting, the in vitro coculture system provided a solid basis to search for distinct and joint soluble matrix- and exosome-mediated effects on functional activities of potential target cells.
LnStr, LuFb, and RAEC, but not LNC and BMC, adhered with high efficacy to the ASMLwt-adhesive fraction (Figure 5A). Thus, the ASMLwt-adhesive fraction may particularly attach to tissue stroma and endothelial cells, which could allow delivery of messages and/or exosomes stored within this matrix.
ASMLwt-CM and, less efficiently, ASMLkd-CM promote LnStr, LuFb, RAEC, and LNC but hardly BMC migration. Migration-promoting activity is restricted to the soluble fraction, whereas exosomes show no effect (Figure 5B).
ASMLwt cells are highly apoptosis-resistant, and apoptosis resistance is reduced in ASMLkd cells [21]. Therefore, we tested for a protective feature of CM on stroma cells. Indeed, ASMLwt-CM and the soluble fraction promote apoptosis resistance of LnStr, LuFb, RAEC, LNC, and BMC. However, a significant increase in cisplatin resistance is only observed in LuFb. Exosomes do not protect from apoptosis (Figure 6, A and B; data not shown).
C-Met expression is reduced in ASMLkd cells and is absent in the ASMLkd-soluble fraction. In addition, ASMLkd-exosomes do not contain HGF, which could affect cell cycle progression. Indeed, LnStr, LuFb, RAEC, LNC, and BMC proliferate in response to ASMLwt-CM, but not ASMLkd-CM, and do not proliferate or weakly proliferate in response to the ASMLkd-soluble fraction. In LnStr, LuFb, RAEC, and LNC, ASMLwt-exosomes but not ASMLkd-exosomes induce the strongest response. Notably, culturing cells with a mixture of the ASMLwt-soluble fraction and ASMLkd-exosomes significantly strengthened proliferative activity (Figure 6C). This finding indicated that weak proliferation induction by ASMLkd-exosomes cannot exclusively rely on the deficit in HGF. Indeed, proliferation of LnStr and LNC was strongly promoted by HGF, independent of whether the cultures contained ASMLwt- or ASMLkd-exosomes. Instead, in LuFb, RAEC, and BMC, slightly increased proliferative activity was seen only on coculture with ASMLkd-exosomes plus HGF (Figure 6D). Thus, besides HGF, additional factors will contribute to the proliferation-supporting activity of ASMLwt-exosomes.
The in vitro analysis confirmed the superior strength of CM compared with the soluble fraction and exosomes and provided evidence for selective contributions of the soluble fraction versus exosomes, which strengthens the in vivo observation that preparation of a (pre)metastatic niche depends on cooperative activity of a CD44v-dependent organization of a tumor-derived soluble fraction and exosomes.
Discussion
Metastasis formation can become promoted by a (pre)metastatic niche [1,5,23]. We hypothesized that a single or few soluble factors may not suffice to fulfill the complex demands of the required long-distance cross talk between a tumor and selected (pre)metastatic organs. Instead, exosomes, which transfer proteins, mRNA, and miRNA to selective targets [27–30], could be suitable candidates. We recently reported that the ASMLkd distinct to the ASMLwt matrix does not promote tumor cell adhesion and apoptosis resistance in vitro. In vivo, ASMLkd cells have lost the high metastatic capacity of ASMLwt cells [21]. Thus, a comparison of ASMLwt- versus ASMLkd-derived factors seemed suited to control our hypothesis. Indeed, ASMLwt-CM supports ASMLkd metastases. Exosomes play an essential role, however, only when assisted by the ASMLwt-soluble fraction.
Consequences of a CD44vkd on CM
The ASMLwt-soluble fraction includes an adhesive subfraction, which contains matrix proteins also found in the corresponding ASMLkd fraction, which is not adhesive [21]. These striking functional differences may be due to the strongly reduced recovery of HAS3 in the ASMLkd-soluble fraction [36] and might be supported by hyaluronidase activity [37], key functions of HA varying considerably with length [36]. The altered assembly of the ASMLkd-“nonadhesive” matrix also may account for the reduced recovery of MMP13, uPA, and HGF, where the reduction of the latter two corresponds with the absence of c-Met and uPAR in the soluble fraction and of HGF in ASMLkd-exosomes.
CD44v6 has been recovered in the ASMLwt-soluble fraction, where differences between ASMLwt and ASMLkd are most pronounced. The absence of c-Met in the ASMLkd-soluble fraction likely is of major importance for reduced metastatic capacity. Activation of c-Met promotes cell survival, supports the epithelial-mesenchymal transition, cell adhesion, and migration, and contributes to angiogenesis [16]. CD44v6 can initiate c-Met activation through HGF binding [17]. Thus, in the absence of CD44v6, c-Met stimulation can become hampered; the consequence of which is reduced transcription of c-Met and c-Met-regulated genes. UPAR, one of the c-Met-regulated genes [16,38], is also strongly downregulated in ASMLkd cells and is absent in the soluble fraction. The absence of CD44v6 can contribute to uPAR downregulation, HA binding of CD44 being described to regulate uPAR transcription [39]. UPAR is involved in uPA binding/plasminogen activation and associates with several integrins, epidermal growth factor receptor (EGFR), PDGFR, caveolin, and vitronectin (VN), thereby initiating signal transduction through focal adhesion kinase, Src, Akt, extracellular receptor-activated kinase, and ras [40]. Thus, uPAR could contribute to (pre)metastatic niche preparation by harboring uPA, which is hardly detectable in the ASMLkd-adhesive matrix, and/or by binding to integrins or EGFR and initiating signal transduction. In ASMLwt cells, CD44v6, c-Met, and uPAR coimmunoprecipitate when cultured in the presence of a chemical cross linker and CD44 cross linking by HA induces c-Met activation (T. Jung, unpublished observations). These observations are in line with the outlined hypothesis and support a central role of CD44v6 in generating a tumor environment that can have a strong impact on premetastatic niche preparation.
C3, although recovered in exosomes, is absent in the ASMLkd-soluble fraction. C3a could become important in (pre)metastatic niche preparation as a most potent anaphylatoxin. C3b may recruit exosomes to monocytes through binding to the CD11b receptor [41]. Notably, as also reported for (pre)metastatic niche formation in mammary cancer [25], very strong clusters of CD11b+ cells were seen in draining LNs and the lung, which has been suggested to be initiated by tumor-derived chemoattractants S100A8 and S100A9 [42].
These differences in the ASMLwt-soluble fraction versus the ASMLkd-soluble fraction are in line with preferentially the ASMLwt-soluble fraction supporting migration and apoptosis resistance of target cells on the way to and within the premetastatic organ. Work is in progress to define the molecular pathways whereby CD44v6 assembles a soluble matrix that supports premetastatic niche formation.
Exosomes can support metastasis formation [43,44]. ASMLwt-exosomes, too, distinct to the soluble fraction, exert some effect on premetastatic niche preparation. These effects, albeit weakened, can also be seen with ASMLkd-exosomes. Therefore, we suggest that the CD44vkd did not affect exosomal components essential for niche preparation but affected components that strengthened the efficacy of exosomes. In our first trial to separate “essential” from “supporting” exosomal components, we differentiated between exosomes derived from distinct membrane domains.
Recovery of tetraspanins (CD9, CD151, D6.1A) and D6.1A-associated proteins (F2 alpha receptor regulatory protein, CD13, INS-2, CD49c, CD49fCD104, EpCAM, claudin-7) [27] is unimpaired in ASMLkd-exosomes. In view of the unaltered tetraspanin web in ASMLkd-exosomes, it becomes likely that 1) invagination of caveolae or clathrin-coated pits [25], but not of tetraspanin microdomains, is affected by a CD44vkd, the reasons of which remain to be defined, and 2) TEM-derived exosomes are essential in (pre)metastatic niche preparation. Tetraspanins are known to be involved in fusion processes [27,45] and, thus, could well contribute to the target cell delivery of exosomes. Unaltered recovery of integrins, including CD11b and integrin ligands (FN and laminin 5) in ASMLkd-exosomes, might additionally contribute to their metastasis-supporting activity together with the ASMLwt-soluble fraction.
However, the CD44vkd affects the recovery of some non-TEM-associated, likely “supporting” exosomal proteins, whose expression is unaltered in ASMLkd cells, which points toward alterations in MVB recruitment: Annexin V binds phosphatidylserine and thereby becomes important in apoptotic signaling [46]. Annexin II is a high-affinity receptor for plasmin and tenascin [47] and can contribute to the integration of tumor-derived exosomes in the soluble tumor matrix. HSPs, including HSP-1, are suggested to activate signaling cascades through binding Toll-like and other receptors [48]. TSP, involved in tumor dormancy by angiogenesis inhibition, also induces a desmoplastic response [49,50]. Monooxygenase activating protein contributes to detoxification of xenobiotics [51]. PGK-1, upregulated in response to oxidative stress, is associated with poor prognosis [52]. Most striking is the absence of HGF in ASMLkd-exosomes, which could well contribute to the lower efficacy of ASMLkd-exosomes supported by the ASMLwt-soluble fraction in premetastatic niche preparation. Although ASMLwt-exosomes contain HGF, proliferation of LnStr and LNC was further strengthened by the addition of HGF. This does not exclude an advantage in premetastatic organ cell stimulation by ASMLwt-exosome-provided HGF. Furthermore, HGF exerted a stronger effect on LnStr and LNC proliferation and also supported LuFb, RAEC, and BMC proliferation in cocultures with ASMLkd-exosomes.
In line with the high recovery of HGF in ASMLwt-exosomes, growth factor/receptor expression becomes upregulated in potential targets and proliferation is strongly promoted. Whether this is partly due to exosomal mRNA translation and exosomal miRNA silencing [31] remains to be explored. The former may account for VEGFR expression in non-endothelial cells, the latter for VEGF, von Willebrand factor, and TSP down-regulation. Both phenomena were only seen after coculture with exosomes. The down-regulation of VEGF could explain the very poorly vascularized ASML tumors [22]. Down-regulation of TSP in exosomal target cells could be a compensatory mechanism, and indeed, there has been a striking increase in the vascularization of (pre)metastatic organs after ASMLwt-CM treatment. A differential analysis of ASMLwt and ASMLkd exosomal mRNA and miRNA and selective knockdowns of the most interesting genes in ASMLwt cells will allow us to answer these questions. Finally, differences in the responsiveness of potential target cells likely are due to the differences in the activation state of genes in the different cells and/or the selective nature of exosome-target interactions [26,28].
Cooperative Activity of the Soluble Fraction and Exosomes
Metastasis formation of ASMLkd cells was strongly promoted by ASMLwt-CM and quite efficiently by a mixture of the ASMLwt-soluble fraction with ASMLkd-exosomes. Ex vivo analysis of draining LNC confirmed that no significant changes in marker profiles were induced by the ASMLwt-soluble fraction. Exclusively, the ASMLwt, but not the ASMLkd-exosomes, promoted few changes: most prominently is a higher percentage of CD11b+ cells. Instead, ASMLwt-CM had a similar impact on protein expression in vivo and in vitro. These findings imply that exosomes contain essential messages for (pre)metastatic niche preparation, which are not delivered or do not reach the premetastatic organ, except if assisted by the soluble fraction or by the adhesive matrix. The fact that the ASMLwt-soluble fraction, which—distinct to the ASMLkd-soluble fraction—contains CD44v, c-Met, uPAR and C3, promotes adhesion, migration, and apoptosis resistance in vitro and makes an active contribution of the soluble matrix to target activation in the premetastatic organ most likely. The adhesive subfraction may also be a store for exosomes as supported by the recovery of HGF. Reaching the target can become facilitated by proteases, which are more abundant in the ASMLwt-soluble fraction. Finally, the adhesive fraction, although not forming a peritumoral matrix, may attach to the lymphatic endothelium, thus serving as a slide bar for exosomes. It should also be noted that the ASMLwt-CM/the soluble matrix plus exosome-induced changes in the premetastatic organs correspond well with the features of a premetastatic niche described so far in several murine models. We are currently evaluating the impact of the soluble matrix, in particular that of CD44v, on exosome transport and activity. We will proceed to clarify the mode of interaction of exosomes with target cells on the way to and within premetastatic organs.
In summary, taking advantage of the loss of metastasis formation by a selective CD44v knockdown in a highly metastatic rat pancreatic adenocarcinoma, which does not form a primary tumor, we demonstrate that CD44v is required for the assembly of a soluble matrix that, in cooperation with exosomes, promotes leukocyte, stroma, and endothelial cell activation in the (pre)metastatic organ. Exosomes are the main actors in (pre)metastatic niche preparation. However, exosomes essentially depend on the support of the soluble tumor-derived fraction, which may serve as an exosome carrier and/or a reservoir for growth factors, chemokines, and proteases.
This is the first demonstration that premetastatic niche preparation requires two components, a soluble matrix that supports exosomes in modulating the target cells in the premetastatic organ. It is also the first report to define the activity of CD44v as a cancer initiating cell marker in tumor progression. Although exemplified in an animal model, these findings are demanding to become controlled for their relevance in human cancer progression.
Supplementary Material
Acknowledgment
Conflict of interest: None of the authors has any conflict of interest.
Abbreviations
- ASMLwt
BSp73ASML
- ASMLkd
CD44v4-v7 knockdown in ASML
- BMC
bone marrow cell
- C3
complement component 3
- CD44v
CD44 variant isoform
- CIC
cancer-initiating cell
- Coll
collagen
- CM
conditioned medium
- FN
fibronectin
- HA
hyaluronic acid
- HAS3
HA synthase 3
- IFP
intrafootpad
- INS-2
intersectin 2
- LNC
lymph node cells
- LnStr
lymph node stroma cells
- LuFb
lung fibroblasts
- RAEC
rat aortic endothelial cell line
- TSP
thrombospondin
- wt
wild type
- VN
vitronectin
Footnotes
This work was supported by the German Research Foundation, SPP1190, the Mildred-Scheel-Stiftung, and the Tumorzentrum Heidelberg/Mannheim (M.Z.).
This article refers to supplementary materials, which are designated by Tables W1 to W3 and Figures W1 to W3 and are available online at www.neoplasia.com.
References
- 1.Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med. 2007;13:535–541. doi: 10.1016/j.molmed.2007.10.004. [DOI] [PubMed] [Google Scholar]
- 2.Regenbrecht CR, Lehrach H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev. 2008;4:319–328. doi: 10.1007/s12015-008-9034-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Werbowetski-Ogilvie TE, Bhatia M. Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends Mol Med. 2008;14:323–332. doi: 10.1016/j.molmed.2008.06.005. [DOI] [PubMed] [Google Scholar]
- 4.Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14:5013–5021. doi: 10.1158/1078-0432.CCR-07-5125. [DOI] [PubMed] [Google Scholar]
- 5.Bidard FC, Pierga JY, Vincent-Salomon A, Poupon MF. A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev. 2008;27:5–10. doi: 10.1007/s10555-007-9103-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124:1111–1115. doi: 10.1016/j.cell.2006.03.011. [DOI] [PubMed] [Google Scholar]
- 7.Marhaba R, Klingbeil P, Nübel T, Nazarenko I, Büchler MW, Zöller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784–804. doi: 10.2174/156652408786733667. [DOI] [PubMed] [Google Scholar]
- 8.Williams DA, Cancelas JA. Leukaemia: niche retreats for stem cells. Nature. 2006;444:827–828. doi: 10.1038/444827a. [DOI] [PubMed] [Google Scholar]
- 9.Khaldoyanidi S. Directing stem cell homing. Cell Stem Cell. 2008;2:198–200. doi: 10.1016/j.stem.2008.02.012. [DOI] [PubMed] [Google Scholar]
- 10.Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–539. doi: 10.1038/nrc1391. [DOI] [PubMed] [Google Scholar]
- 11.Marhaba R, Freyschmidt-Paul P, Zöller M. In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol. 2006;36:3017–3032. doi: 10.1002/eji.200636158. [DOI] [PubMed] [Google Scholar]
- 12.Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008;18:251–259. doi: 10.1016/j.semcancer.2008.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003;46:165–186. doi: 10.1016/s1040-8428(02)00172-5. [DOI] [PubMed] [Google Scholar]
- 14.Fjeldstad K, Kolset SO. Decreasing the metastatic potential in cancers—targeting the heparan sulfate proteoglycans. Curr Drug Targets. 2005;6:665–682. doi: 10.2174/1389450054863662. [DOI] [PubMed] [Google Scholar]
- 15.Matzke A, Sargsyan V, Holtmann B, Aramuni G, Asan E, Sendtner M, Pace G, Howells N, Zhang W, Ponta H, et al. Haploinsufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol Cell Biol. 2007;27:8797–8806. doi: 10.1128/MCB.01355-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–516. doi: 10.1038/nrd2530. [DOI] [PubMed] [Google Scholar]
- 17.Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme? Adv Cancer Res. 2008;101:63–92. doi: 10.1016/S0065-230X(08)00404-1. [DOI] [PubMed] [Google Scholar]
- 18.Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45. doi: 10.1038/nrm1004. [DOI] [PubMed] [Google Scholar]
- 19.Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat. 2008;11:110–121. doi: 10.1016/j.drup.2008.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24. doi: 10.1016/0092-8674(91)90403-l. [DOI] [PubMed] [Google Scholar]
- 21.Klingbeil P, Marhaba R, Jung T, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix crosstalk that supports adhesion and apoptosis resistance. Mol Cancer Res. 2009;7:168–179. doi: 10.1158/1541-7786.MCR-08-0207. [DOI] [PubMed] [Google Scholar]
- 22.Matzku S, Komitowski D, Mildenberger M, Zöller M. Characterization of BSp73, a spontaneous rat tumor and its in vivo selected variants showing different metastasizing capacities. Invasion Metastasis. 1983;3:109–123. [PubMed] [Google Scholar]
- 23.Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23. doi: 10.1016/j.ccr.2004.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827. doi: 10.1038/nature04186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15:35–44. doi: 10.1016/j.ccr.2008.11.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16:415–421. doi: 10.1016/j.ceb.2004.06.003. [DOI] [PubMed] [Google Scholar]
- 27.Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55. doi: 10.1038/nrc2543. [DOI] [PubMed] [Google Scholar]
- 28.Johnstone RM. Exosomes biological significance: a concise review. Blood Cells Mol Dis. 2006;36:315–321. doi: 10.1016/j.bcmd.2005.12.001. [DOI] [PubMed] [Google Scholar]
- 29.Lakkaraju A, Rodriguez-Boulan E. Itinerant exosomes: emerging roles in cell and tissue polarity. Trends Cell Biol. 2008;18:199–209. doi: 10.1016/j.tcb.2008.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gruenberg J, Stenmark H. The biogenesis of multivesicular endosomes. Nat Rev Mol Cell Biol. 2004;5:317–323. doi: 10.1038/nrm1360. [DOI] [PubMed] [Google Scholar]
- 31.Zakharova L, Svetlova M, Fomina AF. T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J Cell Physiol. 2007;212:174–181. doi: 10.1002/jcp.21013. [DOI] [PubMed] [Google Scholar]
- 32.LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer. 2002;100:2–8. doi: 10.1002/ijc.10481. [DOI] [PubMed] [Google Scholar]
- 33.Gobom J, Schuerenberg M, Mueller M, Theiss D, Lehrach H, Nordhoff E. α-Cyano-4-hydroxycinnamic acid affinity sample preparation. A protocol for MALDI-MS peptide analysis in proteomics. Anal Chem. 2001;73:434–438. doi: 10.1021/ac001241s. [DOI] [PubMed] [Google Scholar]
- 34.Gesierich S, Berezovskiy I, Ryschich E, Zöller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006;66:7083–7094. doi: 10.1158/0008-5472.CAN-06-0391. [DOI] [PubMed] [Google Scholar]
- 35.Schmidt DS, Klingbeil P, Schnëlzer M, Zöller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res. 2004;297:329–347. doi: 10.1016/j.yexcr.2004.02.023. [DOI] [PubMed] [Google Scholar]
- 36.Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85:699–715. doi: 10.1016/j.ejcb.2006.05.009. [DOI] [PubMed] [Google Scholar]
- 37.Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci. 2007;80:1921–1943. doi: 10.1016/j.lfs.2007.02.037. [DOI] [PubMed] [Google Scholar]
- 38.Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, et al. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 2008;25:89–96. doi: 10.1007/s10585-007-9106-6. [DOI] [PubMed] [Google Scholar]
- 39.Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer. 2002;102:379–389. doi: 10.1002/ijc.10710. [DOI] [PubMed] [Google Scholar]
- 40.Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 2008;14:5649–5655. doi: 10.1158/1078-0432.CCR-07-4863. [DOI] [PubMed] [Google Scholar]
- 41.Wysoczynski M, Ratajczak J, Reca R, Kucia M, Ratajczak MZ. The third complement component as modulator of platelet production. Adv Exp Med Biol. 2007;598:226–239. doi: 10.1007/978-0-387-71767-8_16. [DOI] [PubMed] [Google Scholar]
- 42.Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10:1349–1355. doi: 10.1038/ncb1794. [DOI] [PubMed] [Google Scholar]
- 43.Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–760. doi: 10.1002/ijc.20657. [DOI] [PubMed] [Google Scholar]
- 44.Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J, Xiang J. Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol. 2006;28:126–131. [PubMed] [Google Scholar]
- 45.Rubinstein E, Ziyyat A, Wolf JP, Le Naour F, Boucheix C. The molecular players of sperm-egg fusion in mammals. Semin Cell Dev Biol. 2006;17:254–263. doi: 10.1016/j.semcdb.2006.02.012. [DOI] [PubMed] [Google Scholar]
- 46.Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527–532. doi: 10.1007/s000180050067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2007;13:3568–3575. doi: 10.2174/138161207782794167. [DOI] [PubMed] [Google Scholar]
- 48.Cappello F, de Macario EC, Marasà L, Zummo G, Macario AJ. Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol Ther. 2008;7:801–809. doi: 10.4161/cbt.7.6.6281. [DOI] [PubMed] [Google Scholar]
- 49.Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008;65:700–712. doi: 10.1007/s00018-007-7486-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Kang SY, Watnick RS. Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS. 2008;116:638–647. doi: 10.1111/j.1600-0463.2008.01138.x. [DOI] [PubMed] [Google Scholar]
- 51.Standop J, Ulrich AB, Schneider MB, Büchler MW, Pour PM. Differences in the expression of xenobiotic-metabolizing enzymes between islets derived from the ventral and dorsal anlage of the pancreas. Pancreatology. 2002;2:510–518. doi: 10.1159/000066093. [DOI] [PubMed] [Google Scholar]
- 52.Jang CH, Lee IA, Ha YR, Lim J, Sung MK, Lee SJ, Kim JS. PGK1 induction by a hydrogen peroxide treatment is suppressed by antioxidants in human colon carcinoma cells. Biosci Biotechnol Biochem. 2008;72:1799–1808. doi: 10.1271/bbb.80079. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.